PTI5803 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 2. The sponsor is PannTheraPi. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product named PTI5803. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
2026-525161-40-00 · Nervous System Diseases
|
Phase 2 | Authorised | PannTheraPi | France |
|
A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.
2026-525162-21-00 · Nervous System Diseases
|
Phase 2 | Authorised | PannTheraPi | France |
| Lead sponsor | Trials |
|---|---|
| PannTheraPi | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named PTI5803, as of the registry sync on 26 September 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.
The lead sponsor is PannTheraPi. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how PTI5803 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PTI5803 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PTI5803 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.